Pet Cancer Therapeutics Market 2019: Application and Future Forecast by 2025

Posted: Updated:

Pet Cancer Therapeutics Market size is set to exceed USD 359.4 million by 2025; according to a new research report by Global Market Insights.

Selbyville, United States – August 6, 2019 /MarketersMedia/

Pet Cancer Therapeutics Market to Hit $359.4 Mn by 2025: Global Market Insights, Inc. Launching of Tanovea-CA1, the FDA approved animal drug for treating canine lymphoma is indeed a breakthrough in pet cancer therapeutics market. Synonymous with lymphosarcoma, this detrimental disease is the most common type of cancer affecting dogs. Center for Veterinary Medicine, a subsidiary of U.S Food and Administration has recently announced a partial approval to this groundbreaking anti-cancer drug and depending upon the effectiveness, market experts anticipates its full approval within few years. A Colorado State University startup, VetDC Inc., is commercially merchandizing these drugs and are presently available in the U.S. market by licensed veterinarians. Reportedly, TANOVEA-CA1 is the only effective animal drug available in pet cancer therapeutics market for the treatment of lymphoma.

In veterinary oncology, chemotherapy is the most recognized therapeutic model that is extensively deployed as one of the most relatively effective methodologies of treatment. In fact, in 2016, chemotherapy held the largest share of the overall pet cancer therapeutics industry. However, as stated by a reputed pet care organization, the goal of chemotherapy treatment in veterinary patients is slightly different from that of human patients. In case of pet cancer treatment, outgrowth of cancer cells is tried to limit as much as possible but not at the cost of their quality of life. However, it has been noticed that cats and dogs respond to chemotherapy much better than humans, which again is pushing pet cancer therapeutics market from chemotherapy.

Get a Sample Copy of this Report@ https://www.gminsights.com/request-sample/detail/2017

Funding impacting the pet cancer therapeutics industry dynamics

Blue Buffalo Foundation and The Petco Foundation have entered a partnership to provide a grant of USD 750000 to Morris Animal Foundation. Reportedly this grand sum of investment is an initiative taken to fund Morris Animal Foundation’s research initiative related to osteosarcoma and other additional studies related to pet cancer. Out of the total grant, USD 500000 is reported to invest in the Foundation’s Osteosarcoma Initiative. Surveys depict that osteosarcoma is a belligerent tumor that is most frequently detected in dogs. The lumpsum grant unquestionably will bring an awareness that would result in an enhancement in the pet cancer therapeutics industry outlook.

As per a recent report put forward by Global Market Insights, Inc., Pet cancer therapeutics market is forecast to exceed a revenue of USD 300 million by 2024, with a projected CAGR of 10% over 2017-2024. Some of the prominent biggies in the pet cancer therapeutics market include Zoetis, Aratana Therapeutics Merial, AB Science, VetDC, Vetivax, Karyopharms Verdinexor, and Regeneus. The industry is rather new and is rapidly expanding with regards to product development and expansive pool of veterinary patients affected with cancers.

U.S. market is expected to reach USD 281.2 million by 2025. Presence of large number of pet drug manufacturing companies, quick adoption of innovative pet care medicines and increasing disposable income of pet owners will boost industry growth.

Australia market is forecasted to grow at 12.6% CAGR across the forecast timeframe. High growth is due to growing pet-keeping trend, availability of innovative pet care medicines and increasing disposable income of pet owners.

Browse Report Summary @ https://www.gminsights.com/industry-analysis/pet-cancer-therapeutics-market

Some of the leading industry players include Zoetis, Merial, Aratana Therapeutics, AB Science, Vetivax, Oasmia Pharmaceutical, VetDC, Regeneus, CanFel Therapeutics, Karyopharms Verdinexor. The most commonly adopted business strategies by industry participants includes new product launches, regional expansion and mergers and acquisition.

U.S. market is expected to reach USD 281.2 million by 2025. Presence of large number of pet drug manufacturing companies, quick adoption of innovative pet care medicines and increasing disposable income of pet owners will boost industry growth.
Australia market is forecasted to grow at 12.6% CAGR across the forecast timeframe. High growth is due to growing pet-keeping trend, availability of innovative pet care medicines and increasing disposable income of pet owners.

Report Content

Chapter 1. Methodology
1.1. Methodology
1.2. Market definition
1.3. Forecast parameters
1.4. Data sources
1.4.1. Secondary
1.4.1.1. Paid sources
1.4.1.2. Unpaid sources
1.4.2. Primary
Chapter 2. Executive Summary
2.1. Pet cancer therapeutics industry 3600 synopsis, 2014 – 2025
2.1.1. Business trends
2.1.2. Medicine type trends
2.1.3. Species trends
2.1.4. Cancer type trends
2.1.5. Regional trends
Chapter 3. Pet Cancer Therapeutics Industry Insights
3.1. Industry segmentation
3.2. Industry landscape, 2014 – 2025
3.3. Industry impact forces
3.3.1. Growth drivers
3.3.1.1. Increasing pet population in the U.S. and Europe
3.3.1.2. Rising prevalence of pet cancer in developed countries
3.3.1.3. Rising awareness of pet owners regarding pet diseases and growing willingness to spend on pet healthcare
3.3.1.4. Growing trend towards new product development
3.3.2. Industry pitfalls & challenges
3.3.2.1. Undesirable effects of pet cancer therapeutics
3.3.2.2. Dearth of veterinary oncologist
3.3.2.3. Low out of pocket expenditure on pet healthcare in developing countries
3.4. Growth potential analysis
3.4.1. By medicine type
3.4.2. By species
3.4.3. By cancer type
3.5. Regulatory landscape
3.5.1. U.S.
3.5.2. Europe
3.6. Technology landscape
3.6.1. U.S.
3.6.2. Europe
3.7. Pipeline analysis
3.8. Porter’s analysis
3.9. Competitive landscape, 2017
3.9.1. Strategy dashboard
3.10. PESTEL analysis

Some of the leading industry players include Zoetis, Merial, Aratana Therapeutics, AB Science, Vetivax, Oasmia Pharmaceutical, VetDC, Regeneus, CanFel Therapeutics, Karyopharms Verdinexor. The most commonly adopted business strategies by industry participants includes new product launches, regional expansion and mergers and acquisition.

Related Insightful Reports@

Bariatric Surgery Devices Market: https://www.marketwatch.com/press-release/bariatric-surgery-devices-market-2018-industry-developments-outlook-current-trends-by-2024-2019-07-31

Biomedical Warming and Thawing Devices Market: https://www.marketwatch.com/press-release/biomedical-warming-and-thawing-devices-market-industry-analysis-2018-and-forecasts-to-2024-2019-07-31

Vascular Graft Market: https://www.marketwatch.com/press-release/vascular-graft-market-2018-industry-growth-by-forecast-to-2024—gmi-analysis-2019-07-31

About Global Market Insights:
Global Market Insights, Inc., headquartered in Delaware, U.S., is a global market research and consulting service provider; offering syndicated and custom research reports along with growth consulting services. Our business intelligence and industry research reports offer clients with penetrative insights and actionable market data specially designed and presented to aid strategic decision making. These exhaustive reports are designed via a proprietary research methodology and are available for key industries such as chemicals, advanced materials, technology, renewable energy and biotechnology.

Contact Us:
Arun Hegde
Corporate Sales, USA
Global Market Insights, Inc.
Phone:1-302-846-7766
Toll Free: 1-888-689-0688
Email: sales@gminsights.com
Web: www.gminsights.com/

Contact Info:
Name: Arun Hegde
Email: Send Email
Organization: Global market insights
Phone: 1-888-689-0688
Website: https://www.gminsights.com/pressrelease/pet-cancer-therapeutics-market

Source URL: https://marketersmedia.com/pet-cancer-therapeutics-market-2019-application-and-future-forecast-by-2025/88903300

Source: MarketersMedia

Release ID: 88903300

Information contained on this page is provided by an independent third-party content provider. Frankly and this Station make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact pressreleases@franklymedia.com